Sign in to view content

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular AMD in High-Risk Eyes (PRO-CON): 24-Month Results

Jeffrey S. Heier, MD

Video
Published 2019

Jeffrey S. Heier, MD

AMD Non-neovascular Symposium

Related

Types of Strokes Seen in Patients
Sophie Jane Bakri, MD
Updates from the Field
2017
Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials
Carl D. Regillo, MD
Annual Meeting Talks
2019
Machine Learning Enabled Outer Retinal OCT Biomarker Extraction for Identification of High-Risk AMD Eyes for Subfoveal Geographic Atrophy Progression
Kubra Sarici, MD
Annual Meeting Talks
2021

Category: AMD-Non-Neovascular

See more